Emblaveo (aztreonam-avibactam) was approved for treating complicated intra-abdominal infections with limited or no treatment options.

Emblaveo will be available in the third quarter of 2025 to treat patients with intra-abdominal infections, a common cause of sepsis in the intensive care unit.

The intravenous antibiotic Emblaveo, a combination of aztreonam and avibactam approved in Europe last year, was developed in ...

Pfizer faces stagnant revenue and patent cliffs. Learn why I downgraded PFE stock to Strong Sell despite a 24.7% YoY growth ...

System1, the creative effectiveness platform, has revealed consumers’ favourite ads from the 2025 Super Bowl: Lay’s, the NFL, ...

Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., ...

Trump could either weaken the negotiations in a way that benefits the pharmaceutical industry, or try to achieve even deeper ...

Eliquis, a blood thinner marketed in partnership with Bristol Myers Squibb, is Pfizer's largest revenue stream at the moment.

The 67th running of the Daytona 500, the Great American Race arrives Sunday at Daytona International Speedway.

Healthcare stocks have something to offer every investor. If you're looking for high growth, you can try an innovative ...